Newmanbrain, a pioneer in neurotechnology and the development of medical devices for objective brain health assessment, has received this recognition that distinguishes the most disruptive medical technologies in Europe. The award values the capacity to transform patient care and provide solutions to current clinical challenges.
The awarded system, Theia®, is a portable and non-invasive functional near-infrared spectroscopy (fNIRS) device powered by artificial intelligence. It is designed as a rapid and accessible tool for screening mild cognitive impairment (MCI), a precursor phase of dementia, allowing for objective assessments in under 20 minutes.
The selection process for the winner combines industry voting with the verdict of a Steering Committee composed of hospital leaders, regulatory experts, and top-tier international investors.
“"Receiving this recognition in a global reference forum like MedTech World represents a fundamental validation for our technology and our team. This award reinforces our roadmap to accelerate its clinical deployment, fostering new alliances with hospitals and facilitating our international expansion."
With this award, Newmanbrain consolidates its position in European health innovation and opens new avenues for collaboration. The company, driven by the UMH Science Park, already holds European MDR certification for Theia® and specializes in advanced portable neuroimaging and artificial intelligence solutions.




